Log in

Relevant bibliographies by topics / CD52 antigen

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers

Academic literature on the topic 'CD52 antigen'

Author: Grafiati

Published: 4 June 2021

Last updated: 14 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'CD52 antigen.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "CD52 antigen"

1

Wagner, Eva M., Aline N. Lay, Timo Schmitt, et al. "Long-Term Persistence of Functionally Altered GPI-Anchor Negative T-Cell Subsets After Alemtuzumab-Based T-Cell Depleted Hematopoietic Stem Cell Transplantation." Blood 114, no. 22 (2009): 2438. http://dx.doi.org/10.1182/blood.v114.22.2438.2438.

Full text

Abstract:

Abstract Abstract 2438 Poster Board II-415 The anti CD52 antibody alemtuzumab is frequently used for in vivo T cell depletion (TCD) in the context of allogeneic hematopoietic stem cell transplantation (HSCT). We have recently demonstrated the persistence of CD52-negative T-cell subsets in patients after HSCT following alemtuzumab-mediated TCD (Meyer, Wagner et al., Bone Marrow Transplantation 2009). The loss of CD52 among lymphocytes was exclusively related to T cells and was more prominent in CD4 compared to CD8 T cells. CD8-depleted donor-lymphocyte infusions (DLI) increased the percentage o

APA, Harvard, Vancouver, ISO, and other styles

2

Loeff, Floris C., Esther H. M. van Egmond, Judith Olde Wolbers, J. H. Frederik Falkenburg, Constantijn J. M. Halkes, and Inge Jedema. "Effectivity Of Complement-Dependent Cytotoxicity Induced By Therapeutic Antibodies In Acute Lymphoblastic Leukemia Is Dictated By Antigen Expression Levels and Curtailed By Membrane-Bound Complement Regulatory Proteins." Blood 122, no. 21 (2013): 3909. http://dx.doi.org/10.1182/blood.v122.21.3909.3909.

Full text

Abstract:

Abstract Membrane-bound complement regulatory proteins (mCRPs) are known to protect cells from bystander lysis and spontaneous activation of complement. In the case of antibody therapy these mCRP’s may down-modulate antibody-induced complement-dependent cytotoxicity (CDC). Two of these mCRPs, CD55 (DAF) and CD59 (MIRL), have been suggested as modulators of CDC. However, no strong correlation between their expression level and target cell lysis has been demonstrated thus far. Our goal was to elucidate the role of these mCRPs in the efficacy of antibody-induced CDC. We tested the effectivity of

APA, Harvard, Vancouver, ISO, and other styles

3

Jagoda, Krystyna, Sebastian Giebel, Beata Stella-Holowiecka, Malgorzata Krawczyk-Kulis, and Jerzy Holowiecki. "CD52 and CD20 as Potential Targets for Anti-Leukemic Immunotherapy in Adult Acute Lymphoblastic Leukemia." Blood 104, no. 11 (2004): 4403. http://dx.doi.org/10.1182/blood.v104.11.4403.4403.

Full text

Abstract:

Abstract CD52 and CD20 are potential targets for immunotherapy of adult acute lymphoblastic leukemia (ALL) with the use of commercially available humanized monoclonal antibodies (MoAbs) (alemtuzumab, rituksimab, etc.). Altough 20% antigen expression is considered diagnostic, it is thought that only patients with &gt;50% and preferably those with &gt;80% leukemic blasts expressing particular antigen are candidates for the treatment with the use of MoAbs. The efficiacy of immunotherapy depends, however, not only on the proportion of lymphoblasts bearing particular marker but also on the

APA, Harvard, Vancouver, ISO, and other styles

4

Hoelzer, Dieter. "Novel Antibody-Based Therapies For Acute Lymphoblastic Leukemia." Hematology 2011, no. 1 (2011): 243–49. http://dx.doi.org/10.1182/asheducation-2011.1.243.

Full text

Abstract:

AbstractA major breakthrough in the treatment of acute lymphoblastic leukemia (ALL) was the availability of targeted therapies targeting either specific transcripts, such as bcr-abl fusion protein by tyrosine kinase inhibitors (TKIs), or specific antigens by mAbs. ALL blast cells express a variety of specific antigens (eg, CD19, CD20, CD22, CD33, and CD52) that serve as targets for mAbs. To date, the most data are available for anti-CD20 (rituximab), which has been combined with chemotherapy for the treatment of mature B-ALL/Burkitt lymphoma. Studies with rituximab have also been completed in

APA, Harvard, Vancouver, ISO, and other styles

5

Hoermann, Gregor, Katharina Blatt, Harald Herrmann, et al. "Identification of Campath-1 Antigen (CD52) As a Novel Therapeutic Target in Advanced Systemic Mastocytosis." Blood 120, no. 21 (2012): 2866. http://dx.doi.org/10.1182/blood.v120.21.2866.2866.

Full text

Abstract:

Abstract Abstract 2866 Systemic mastocytosis (SM) is a neoplasm of mast cells (MC) and MC progenitor cells. The clinical picture in SM ranges from an indolent course to highly aggressive cases with short survival time. In a majority of all patients with SM, the KIT mutation D816V is detectable. In addition, activating RAS mutations have recently been identified in patients with advanced SM. So far, no curative therapy for advanced SM is available. To identify molecular targets in neoplastic MC, we have generated novel human MC lines by lentiviral immortalization of cord blood-derived MC progen

APA, Harvard, Vancouver, ISO, and other styles

6

Ratzinger, Gudrun, John L. Reagan, Glenn Heller, Klaus J. Busam, and James W. Young. "Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation." Blood 101, no. 4 (2003): 1422–29. http://dx.doi.org/10.1182/blood-2002-04-1093.

Full text

Abstract:

Alemtuzumab (anti-CD52; Campath 1-H) depletes both host and donor T cells when used in preparative regimens for allogeneic transplantation. This promotes engraftment even after nonmyeloablative conditioning and limits graft-versus-host disease (GVHD) even after unrelated or major histocompatibility complex (MHC) disparate allografts. We asked whether anti-CD52 differentially targets antigen-presenting cells (APCs), in addition to depleting T cells. Monocyte-derived dendritic cells (moDCs) expressed abundant CD52 as expected. Langerhans cells (LCs) and dermal-interstitial DCs (DDC-IDCs), howeve

APA, Harvard, Vancouver, ISO, and other styles

7

Lones, Mark, and Ivan Kirov. "Cell Surface Targets for Monoclonal Antibody Therapy in Lymphoid Neoplasms of Children and Adolescents." Blood 104, no. 11 (2004): 4544. http://dx.doi.org/10.1182/blood.v104.11.4544.4544.

Full text

Abstract:

Abstract Recently, monoclonal antibodies have become available for treatment of lymphoid neoplasms in adults, but have not been studied in children and adolescents. These monoclonal antibodies are directed against cell surface antigens CD20 (Rituximab, Ibritumomab-Tiuxetan, Tositumomab), CD22 (Epratuzumab), CD52 (CAMPATH-1H), HLA-DR Beta-chain (Hu1D10), CD23 (IDEC-152), and CD33 (Gemtuzumab Ozogamicin). The objective of this study is to identify cell surface targets eligible for monoclonal antibody therapy in lymphoid neoplasms of children and adolescents. This is a retrospective analysis of l

APA, Harvard, Vancouver, ISO, and other styles

8

Guarini, Anna, Maria Stefania De Propris, Stefania Intoppa, et al. "Quantification of CD52 Antigen Expression by Normal and Leukemic Lymphoid Cells: Indications for Anti-CD52 Antibody Therapy?." Blood 106, no. 11 (2005): 3918. http://dx.doi.org/10.1182/blood.v106.11.3918.3918.

Full text

Abstract:

Abstract CD52 is a glycosyl-phosphatidylinositol-anchored protein expressed on the surface of lymphoid cells. Polyclonal and monoclonal anti-CD52 antibodies have been utilized to purge T-lymphocyte populations from the peripheral blood and bone marrow in allogeneic transplantation procedures to prevent graft-versus-host disease. Nowadays, the anti-CD52 monoclonal antibody represents an established tool for the treatment of acute and chronic lymphoproliferative disorders. In this study, we have quantified the levels of expression of the CD52 antigen on the surface of normal B- and T-cell popula

APA, Harvard, Vancouver, ISO, and other styles

9

Lozanski, Gerard, Ben Sanford, Daohai Yu, et al. "CD52 Expression in Adult Acute Lymphoblastic Leukemia (ALL): Quantitative Flow Cytometry Provides New Insights." Blood 108, no. 11 (2006): 2293. http://dx.doi.org/10.1182/blood.v108.11.2293.2293.

Full text

Abstract:

Abstract We recently tested the feasibility of incorporating Alemtuzumab, a humanized anti-CD52 monoclonal antibody, into frontline therapy of adult ALL (CALGB 10102) in an attempt to eradicate minimal residual disease (MRD). We have previously reported that CD52 expression occurs in 68% of newly diagnosed ALL. This assessment was based upon the use of a qualitative flow cytometric assay performed on all pre-treatment cases in a central CALGB reference laboratory. Cases with > 10% CD52 expression on lymphoblasts relative to an isotype control were considered CD52 positive and eligible to re

APA, Harvard, Vancouver, ISO, and other styles

10

Elsner, J., R. Hochstetter, K. Spiekermann, and A. Kapp. "Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils." Blood 88, no. 12 (1996): 4684–93. http://dx.doi.org/10.1182/blood.v88.12.4684.bloodjournal88124684.

Full text

Abstract:

Eosinophilic and neutrophilic granulocytes represent major effector cells in the inflammatory response. Whereas neutrophils are predominantly involved in bacterial infections, eosinophils are of essential importance in the allergic inflammation. Surface markers have been used to distinguish neutrophils (CD16+) from eosinophils (CD16-) and might indicate different functional properties of these cells. In this study, expression and functional activity of CD52 on human eosinophils and neutrophils was investigated in nonatopic healthy donors and from patients with hypereosinophilia. Flow cytometri

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "CD52 antigen"

1

Taylor, Vanessa Claire. "Biology of the CD52 antigen, a major glycoprotein of human lymphocytes." Thesis, University of Cambridge, 1995. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.242883.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Rowan, Wendy Caroline. "Characterisation of function and regulation of the CD52 antigen on T and B lymphocytes." Thesis, Imperial College London, 1999. http://hdl.handle.net/10044/1/7566.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Shao, Ning. "SYNTHETIC STUDIES OF GLYCOPEPTIDES AND GLYCOCONJUGATES." Case Western Reserve University School of Graduate Studies / OhioLINK, 2005. http://rave.ohiolink.edu/etdc/view?acc_num=case1105557527.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Navenot, Jean-Marc. "Diagnostic et suivi biologique de l'hemoglobinurie nocturne paroxystique : contribution a l'etude de la physiopathologie." Nantes, 1996. http://www.theses.fr/1996NANT15VS.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Otipoby, Kevin L. "CD22 regulates B cell fate via two signaling domains within its cytoplasmic tail /." Thesis, Connect to this title online; UW restricted, 2000. http://hdl.handle.net/1773/8335.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Haas, Karen Marie. "Induction and regulation of bovine B lymphocyte responses /." free to MU campus, to others for purchase, 2000. http://wwwlib.umi.com/cr/mo/fullcit?p9999290.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Brown, Marion Hanbury. "Physical interactions of the CD2 antigen." Thesis, Open University, 1990. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.277634.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Haas, Karen M. "Induction and regulation of bovine B lymphocyte responses." free to MU campus, to others for purchase, 2000. http://wwwlib.umi.com/cr/mo/fullcit?p9999290.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Klein, Jörg. "Verwendung von Gene-Targeting-Techniken zur Etablierung neuer Mauslinien mit Mutationen in B-Zell-Signalwegen." [S.l.] : [s.n.], 2005. http://deposit.ddb.de/cgi-bin/dokserv?idn=976107953.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Mischke, Dirk. "Generierung regulatorischer T-Zellen aus naiven CD4+-CD45RA+-T-Zellen durch Anti-CD4-Interaktion." Berlin wvb, Wiss. Verl, 2007. http://www.wvberlin.de/data/inhalt/mischke_dirk.html.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "CD52 antigen"

1

A, Herzenberg Leonore, Haughton Geoffrey, and Rajewsky K. 1936-, eds. CD5 B cells in development and disease. New York Academy of Sciences, 1992.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

(Editor), B. Kyewski, and Elisabeth Suri-Payer (Editor), eds. CD4+CD25+ Regulatory T Cells: Origin, Function and Therapeutic Potential (Current Topics in Microbiology and Immunology). Springer, 2005.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "CD52 antigen"

1

Hasegawa, Akiko, and Koji Koyama. "Sperm-Immobilizing Antibody and Its Target Antigen (CD52)." In Immune Infertility. Springer Berlin Heidelberg, 2009. http://dx.doi.org/10.1007/978-3-642-01379-9_11.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

van Roy, Frans, Volker Nimmrich, Anton Bespalov, et al. "CD53 Antigen." In Encyclopedia of Signaling Molecules. Springer New York, 2012. http://dx.doi.org/10.1007/978-1-4419-0461-4_100212.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

van Roy, Frans, Volker Nimmrich, Anton Bespalov, et al. "CD72 Antigen." In Encyclopedia of Signaling Molecules. Springer New York, 2012. http://dx.doi.org/10.1007/978-1-4419-0461-4_100216.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Sherwood, Amanda R., Vikas V. Dukhande, Matthew S. Gentry, et al. "Leukocyte Surface Antigen CD53." In Encyclopedia of Signaling Molecules. Springer New York, 2012. http://dx.doi.org/10.1007/978-1-4419-0461-4_100700.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Cantel, S., A. Kavishwar, M. Schlimme, A. Khatri, J. A. Halperin, and M. Chorev. "Glycated-CD59 antigen: exploration of synthetic approaches." In Advances in Experimental Medicine and Biology. Springer New York, 2009. http://dx.doi.org/10.1007/978-0-387-73657-0_141.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Tsubata, Takeshi, Chisato Wakabayashi, and Takahiro Adachi. "Regulation of B-cell antigen receptor signaling by CD72." In Activating and Inhibitory Immunoglobulin-like Receptors. Springer Japan, 2001. http://dx.doi.org/10.1007/978-4-431-53940-7_16.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Cornall, R. J., C. C. Goodnow, and J. G. Cyster. "Regulation of B Cell Antigen Receptor Signaling by the Lyn/CD22/SHP1 Pathway." In Current Topics in Microbiology and Immunology. Springer Berlin Heidelberg, 1999. http://dx.doi.org/10.1007/978-3-642-58537-1_5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Hünig, T., G. Tiefenthaler, E. Schlipköter, and A. Lawetzky. "The T-Cell Antigen Receptor and CD2 in Rat T-Cell Activation and Ontogeny." In Progress in Immunology. Springer Berlin Heidelberg, 1989. http://dx.doi.org/10.1007/978-3-642-83755-5_19.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Takei, Takashi, Yoshifumi Ishii, Shinichiro Kon, Junichiro Fujimoto, and Kokichi Kikuchi. "Determinant Heterogeneity of CD5, CD8, and CD4 Antigen Molecules as Defined by Monoclonal Antibodies." In Leukocyte Typing II. Springer New York, 1986. http://dx.doi.org/10.1007/978-1-4613-8587-5_21.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Barclay, A. Neil, Marion H. Brown, S. K. Alex Law, Andrew J. McKnight, Michael G. Tomlinson, and P. Anton van der Merwe. "CD52." In The Leucocyte Antigen FactsBook. Elsevier, 1997. http://dx.doi.org/10.1016/b978-012078185-0/50491-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "CD52 antigen"

1

Benjamin, Reuben, Maud Condomines, Gertrude Gunset, and Michel Sadelain. "Abstract 3499: CD56 targeted chimeric antigen receptors for immunotherapy of multiple myeloma." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-3499.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Ross, Savannah, Asen Bagashev, Dina Schneider, Peirong Hu, Sarah Tasian, and Terry Fry. "Abstract 3234: Multi-antigen targeting of CD19, CD22 and TSLPR to prevent Ph-like ALL resistance." In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-3234.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Carrigan, Christina N., Shanqin Xu, Yiwei Zhao, et al. "Abstract 5335: The antigen target of IMGN901, CD56, is expressed at significant levels in merkel cell carcinoma (MCC)." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-5335.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Haso, Waleed, Daniel Lee, Richard Morgan, Ira Pastan, Crystal Mackall, and Rimas J. Orentas. "Abstract 3504: Generation and optimization of a chimeric antigen receptor against human CD22: A new immunotherapeutic agent for adoptive immunotherapy." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-3504.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Heckel, Diana, Michelle Padget, Srujana Cherukuri, et al. "Abstract 3385: Expression of CD22, a late B lymphoid antigen, does not distinguish leukemia stem cells from the bulk population in acute lymphoblastic leukemia cases." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-3385.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!